175 related articles for article (PubMed ID: 36730269)
1. Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.
Dougherty J; Harvey K; Liou A; Labella K; Moran D; Brosius S; De Raedt T
PLoS One; 2023; 18(2):e0277305. PubMed ID: 36730269
[TBL] [Abstract][Full Text] [Related]
2. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
3. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
4. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.
Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB
Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698
[TBL] [Abstract][Full Text] [Related]
7. Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-Developmental and epileptic encephalopathy and optic pathway glioma.
Barrière S; Faure-Conter C; Leblond P; Philippe M; des Portes V; Lion François L; de Bellescize J; Sabatier I
Epileptic Disord; 2024 Feb; 26(1):133-138. PubMed ID: 37983638
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
9. Global microRNA profiling identified miR-10b-5p as a regulator of neurofibromatosis 1 (NF1)-glioma migration.
Nix JS; Yuan M; Imada EL; Ames H; Marchionni L; Gutmann DH; Rodriguez FJ
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):96-107. PubMed ID: 32603552
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
11. Genomic Status of
Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
[TBL] [Abstract][Full Text] [Related]
12. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
14. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma.
Solga AC; Gianino SM; Gutmann DH
Oncogene; 2014 Jan; 33(3):289-99. PubMed ID: 23318450
[TBL] [Abstract][Full Text] [Related]
15. Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.
Monroe CL; Dahiya S; Gutmann DH
Annu Rev Pathol; 2017 Jan; 12():53-74. PubMed ID: 28135565
[TBL] [Abstract][Full Text] [Related]
16. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.
Kobayashi D; Hirayama M; Komohara Y; Mizuguchi S; Wilson Morifuji M; Ihn H; Takeya M; Kuramochi A; Araki N
J Biol Chem; 2014 Sep; 289(38):26314-26326. PubMed ID: 25092287
[TBL] [Abstract][Full Text] [Related]
17. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
18. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
19. Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma.
Brossier NM; Thondapu S; Cobb OM; Dahiya S; Gutmann DH
Neuro Oncol; 2021 Apr; 23(4):625-637. PubMed ID: 33080011
[TBL] [Abstract][Full Text] [Related]
20. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.
Brown JA; Gianino SM; Gutmann DH
J Neurosci; 2010 Apr; 30(16):5579-89. PubMed ID: 20410111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
